H 1-antihistamine up-dosing in chronic spontaneous urticaria: Patients' perspective of effectiveness and side effects - a retrospective survey study

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Weller, Karsten ^a   Ziege, Claudia ^a   Staubach, Petra ^b   Brockow, Knut ^c   Siebenhaar, Frank ^a   Krause, Karoline ^a   Altrichter, Sabine ^a   Church, Martin K ^a   Maurer, Marcus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CETIRIZINE; CLEMASTINE; DESLORATADINE; DIMETINDENE; EBASTINE; FEXOFENADINE; HYDROXYZINE; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; PROMETHAZINE; RUPATADINE; HISTAMINE H1 RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; ATTITUDE TO HEALTH; CHRONIC SPONTANEOUS URTICARIA; CONTROLLED STUDY; DISEASE CONTROL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HEALTH BELIEF; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; QUESTIONNAIRE; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SEDATION; SELF CONCEPT; SIDE EFFECT; URTICARIA; CHRONIC DISEASE; TREATMENT OUTCOME;

ADULT; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEALTH SURVEYS; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URTICARIA;

EID: 80052349904     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023931     Document Type: Article

References (25)

1. Zuberbier T, Asero R, Bindslev-Jensen C, Walter CG, Church MK, et al. (2009) EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 64: 1417-1426.
2. Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, et al. (2011) Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 66: 317-330.
3. van der Valk PG, Moret G, Kiemeney LA, (2002) The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol 146: 110-113.
4. Toubi E, Kessel A, Avshovich N, Bamberger E, Sabo E, et al. (2004) Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 59: 869-873.
5. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW, (1997) The impact of chronic urticaria on the quality of life. Br J Dermatol 136: 197-201.
6. Poon E, Seed PT, Greaves MW, Kobza-Black A, (1999) The extent and nature of disability in different urticarial conditions. Br J Dermatol 140: 667-671.
7. Grob JJ, Revuz J, Ortonne JP, Auquier P, Lorette G, (2005) Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 152: 289-295.
8. Zuberbier T, Asero R, Bindslev-Jensen C, Walter CG, Church MK, et al. (2009) EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. Allergy 64: 1427-1443.
9. Zuberbier T, Munzberger C, Haustein U, Trippas E, Burtin B, et al. (1996) Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology 193: 324-327.
10. Kameyoshi Y, Tanaka T, Mihara S, Takahagi S, Niimi N, et al. (2007) Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: an open study of 21 patients. Br J Dermatol 157: 803-804.
11. Gimenez-Arnau A, Izquierdo I, Maurer M, (2009) The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol 23: 1088-1091.
12. Metz M, Scholz E, Ferran M, Izquierdo I, Gimenez-Arnau A, et al. (2010) Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol 104: 86-92.
13. Asero R, (2007) Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol 32: 34-38.
14. Godse KV, Nadkarni NJ, Jani G, Ghate S, (2010) Fexofenadine in higher doses in chronic spontaneous urticaria. Indian Dermatol Online J 1: 45-46.
15. Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M, (2009) High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 123: 672-679.
16. Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, et al. (2010) The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 125: 676-682.
17. Simons FE, (1994) H1-receptor antagonists. Comparative tolerability and safety. Drug Saf 10: 350-380.
18. Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, et al. (2010) Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy 65: 459-466.
19. Simons FE, Silver NA, Gu X, Simons KJ, (2002) Clinical pharmacology of H1-antihistamines in the skin. J Allergy Clin Immunol 110: 777-783.
20. Simons FE, (1999) H1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol 83: 481-488.
21. Simons FE, (2004) Advances in H1-antihistamines. N Engl J Med 351: 2203-2217.
22. Devillier P, Roche N, Faisy C, (2008) Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin Pharmacokinet 47: 217-230.
23. Maurer M, Ortonne JP, Zuberbier T, (2009) Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. Br J Dermatol 160: 633-641.
24. Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T, (2002) Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 22: 511-515.
25. Verster JC, Volkerts ER, (2004) Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol 92: 294-303.